Consistent with findings from studies on small-cell lung cancer (SCLC), where WBP5 knockdown reduced drug resistance, our study reveals that the reduction in WBP5 in HNSCC enhanced responsiveness to cisplatin. This evidence concerns the gene TCEAL9 and small cell lung carcinoma.